ArticleVirus research2026
Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and the elderly, with limited treatment options. Venenum bufonis (Vb), a traditional Chinese medicine, exhibits broad pharmacological activities including antiviral and anti-inflammatory effects, but its potential against RSV-induced pneumonia remains unclear. This study evaluates Vb's therapeutic effects and mechanisms in RSV-infected pneumonia and identifies its key active constituents. RSV pneumonia was induced in C57BL/6 mice via intranasal inoculation. Mice were treated with Vb or ribavirin intraperitoneally for five days. Lung pathology, viral gene, inflammatory cytokine gene expression, NLRP3 pathway activation, and immune cell infiltration were assessed using H&E staining, electron microscopy, RT-qPCR, immunohistochemistry, RNA sequencing and flow cytometry. The results demonstrated that Vb treatment significantly reduced lung tissue damage, mRNA levels of RSV-N protein, proinflammatory cytokines (TNF-α, IL-6) and type II interferon (IFN-γ), and enhanced the mRNA levels of type I interferons (IFN-α/β). Furthermore, Vb markedly decreased macrophage infiltration and suppressed mRNA expression of NLRP3, Caspase-1, and IL-1β in lung tissue, suggesting it may alleviate RSV pneumonia by inhibiting macrophage-driven inflammation and NLRP3 activation. Additionally, bufalin, cinobufagin, and resibufogenin were identified as likely bioactive constituents mediating Vb's therapeutic effects. This study provides a scientific basis for the potential application of Vb in the treatment of RSV-induced pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.